
Cupid Limited just delivered the kind of quarter that makes investors sit up and take notice. Net profit for Q2 FY27 jumped 133% year-on-year to Rs 56.2 crore, while revenue from operations surged 122% to Rs 187.9 crore. The stock hit a fresh 52-week high of Rs 389, extending a rally that has delivered over 577% returns in just one year. But here's the thing—this isn't just about one strong quarter. The company simultaneously raised its FY27 revenue guidance to Rs 880 crore or more, up from an original target of Rs 600 crore. That's a 47% upgrade in a single year. When a company keeps raising the bar like this, it's worth asking what's really driving the growth and whether the valuation has gotten ahead of itself.
Let's break down the Rs 56.2 crore profit number. The core business performed well—EBITDA came in at Rs 54.8 crore with a 29% margin. But there's more to the story. Other income jumped to Rs 21.1 crore in Q2, compared to just Rs 5.8 crore a year earlier. The company also recorded a Rs 20 crore gain from changes in the fair value of investments. These non-operating items mean that part of the profit growth isn't from selling condoms or diagnostic kits—it's from financial moves that may not repeat every quarter. Investor Presentation
On the operational side, the story is about scale and mix.
The Consumer Healthcare & FMCG segment alone generated Rs 166.9 crore, or 49% of sales. This is a big shift from Cupid's historical reliance on export tenders. Meanwhile, international business still matters—exports contributed Rs 112.7 crore in H1, supported by institutional demand through the PFSCM agreement and South Africa's national programme. Price revisions across the export portfolio also helped improve realizations.
Here's where it gets interesting. While revenue grew faster than expenses overall, raw material costs rose to about 52% of operating income in Q2, compared to 41% a year earlier. That's the main pressure point on margins. Employee costs and other expenses actually fell as a percentage of revenue, showing operating leverage—the company is spreading fixed costs over a larger sales base. The net margin improved to 30% from 29% a year ago, but the Q2 EBITDA margin of 29% was lower than the H1 margin of 33.5%. This suggests that while volumes are growing, input costs are rising too.
Cupid didn't just beat expectations—it raised the bar for the future.
For context, the company had initially guided Rs 600 crore revenue and Rs 180 crore profit, then upgraded to Rs 725-750 crore in September. The latest upgrade reflects strong H1 performance—H1 revenue of Rs 342.6 crore is already about 42% of the revised target. But hitting Rs 880 crore requires H2 revenue of roughly Rs 537 crore, which is about 57% higher than H1. That's a steep step-up. Investor Presentation
What's driving this confidence? Three main factors. First, the Palava manufacturing facility in Maharashtra is scheduled for commissioning in Q3 FY27, which will more than double male condom capacity to 1.25 billion units annually and female condom capacity to 125 million units. Second, new retail partnerships are kicking in—the V2 Retail partnership is expected to contribute at least Rs 400 crore over the next 12 months, while Style Baazar should add about Rs 200 crore in FY27. Third, management expects H2 to be the strongest half-year in the company's history, driven by festive demand and accelerating consumer traction.
Now, let's talk about the stock. Cupid's market capitalization has swelled to around Rs 47,600-51,150 crore. The stock trades at a reported P/E ratio of 347.8x and a P/B ratio of 105.5x.
Cupid's valuation is in a different universe. Even if we look at forward multiples based on guided profits, the stock trades at roughly 186x FY27 earnings, 131x FY28, and 85x FY29. That assumes the company executes perfectly on its guidance and that the market continues to award a premium multiple.
The 5-year return of over 16,000% is staggering, but it comes from a very low base—the stock traded around Rs 50 just a year ago. Promoters have increased their stake to 47.7%, and foreign institutional investors now hold 4.7%. The technical picture is strong, with the stock trading above all key moving averages. But at these valuations, the room for error is minimal. Any miss on guidance, margin pressure from raw materials, or delays in the Palava commissioning could trigger a sharp correction.
The broader condom market is growing, but not at Cupid's pace. Industry estimates suggest the India condom market is growing at 8-10% annually, reaching roughly Rs 2,000-3,500 crore by the early 2030s. Cupid's growth is clearly about market share gains and category expansion, not just industry tailwinds. The company is differentiating through product innovation—27 male condom SKUs ranging from Rs 30 to Rs 300, nitrile female condoms, and 15 IVD diagnostic kits. It's also expanding into new FMCG categories like hair removal spray, face wash, and perfumes under brands like Cupid Angel and NiVi. Investor Presentation +2
But competition is intense. The top five players control an estimated 76% of the Indian condom market. Established brands like Durex (Reckitt Benckiser) and Manforce (Mankind Pharma) have strong brand recognition and deep pockets for marketing. Cupid's strategy focuses on organized retail partnerships and export tenders, but this comes with risks. The export business is tender-dependent and lumpy, accounting for 59% of FY26 revenue. Raw material costs, particularly latex and petroleum-linked chemicals, are volatile and have already prompted price hikes by competitors. Local manufacturing requirements in Africa and the GCC could also impact export share. Investor Presentation +1
Cupid's Q2 performance is undeniably impressive. The company is successfully transitioning from an export-led tender business to a diversified consumer healthcare player with strong domestic growth. The raised guidance reflects confidence in capacity expansion, retail partnerships, and product mix improvements. But the valuation has priced in perfection. At current multiples, the stock assumes sustained high growth, margin expansion, and a continued premium valuation multiple. The key things to watch in the coming quarters are whether H2 delivers the required 1.6x step-up over H1, how raw material costs trend, and whether the Palava facility ramps up on schedule. For now, Cupid is firing on all cylinders—but in the stock market, today's hero can quickly become tomorrow's cautionary tale if expectations aren't met.